Zenas BioPharma
Zenas BioPharma's revenue rose 100.0% to $10 million in fiscal 2025. Its operating margin was −3,830.6%, down from −3,277.8% a year earlier. Free cash flow was −$172 million. The diluted share count rose 238.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Zenas BioPharma does
Zenas BioPharma is a clinical-stage biopharmaceutical company building a business in immunology and inflammation, mainly treatments for autoimmune diseases. It has no products approved for sale. Its strategy is to acquire drug candidates, then develop them using its own team and outside resources.
Its lead candidate, obexelimab, is an antibody designed to bind two proteins on B cells, a type of immune cell, called CD19 and FcγRIIb. The company says this is meant to calm the cells that drive many autoimmune diseases without wiping them out, and it believes this could avoid some drawbacks of drugs that deplete B cells. It is testing obexelimab in immunoglobulin G4-related disease (IgG4-RD), in a Phase 3 trial that reported topline data in January 2026, in relapsing multiple sclerosis in a Phase 2 trial that reported in October 2025, and in systemic lupus erythematosus in an ongoing Phase 2 trial.
Zenas does not yet earn revenue from product sales. It says it hopes to build obexelimab into a family of treatments for several autoimmune diseases.
Its biggest risks, as it describes them
- It is an early-stage company with no approved products and large losses.
- Its auditor has expressed substantial doubt about its ability to continue as a going concern.
- It needs substantial new financing, which could dilute stockholders or limit its operations.
- Trials may be delayed by slow patient enrollment, and side effects could stop approval.
- Its lead drug, obexelimab, may not succeed across its target diseases.
Income statement
Zenas BioPharma lost money in fiscal 2025: a net loss of $378 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 57 | 351 | 360 |
| Debt incl. finance leases | 20 | — | 79 |
| Net debt (negative means net cash) | −37 | — | −282 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | 0.3x |
| Interest coverage | — | — | −52.3x |
| Current ratio | 2.6x | 6.2x | 5.6x |
| Quick ratio | 2.6x | 6.2x | 5.6x |
Cash flow
Projections
Project Zenas BioPharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Zenas BioPharma reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −2,486.1% | −1,623.5% |
| Altman Z'' | 4.61 | −6.48 |
| Accruals ratio | −17.0% | −54.5% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Zenas BioPharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zenas BioPharma | FY25 | 100.0% | −3,830.6% | −1,723.5% | — | — | — | |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 50 | 5 | 10 |
| Revenue growth | — | −90.0% | 100.0% |
| Gross profit | — | — | — |
| Research and development | 60 | 139 | 168 |
| Operating income | −37 | −164 | −383 |
| Net income | −37 | −157 | −378 |
| Diluted EPS (US$) | −24.25 | −11.89 | −8.44 |
| Diluted shares (millions) | 2 | 13 | 45 |
| Cash flow | |||
| Cash from operations | −30 | −120 | −172 |
| Capital expenditure | 0 | 0 | 0 |
| Free cash flow | −31 | −120 | −172 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 4 | 11 | 26 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 57 | 351 | 360 |
| Debt incl. finance leases | 20 | — | 79 |
| Total assets | 68 | 370 | 384 |
| Total liabilities | 44 | 58 | 142 |
| Shareholders' equity | −226 | 312 | 242 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −74.3% | −3,277.8% | −3,830.6% |
| Net margin | −74.2% | −3,139.8% | −3,777.4% |
| Free cash flow margin | −61.1% | −2,396.1% | −1,723.5% |
| Rule of 40 (growth + FCF margin) | — | −2,486.1% | −1,623.5% |
| Return on capital | — | — | — |
| Return on equity | — | −362.0% | −136.2% |
| Return on assets | — | −71.7% | −100.2% |
| Net debt to EBITDA | — | — | — |